

October 22, 2018



## ContraFect to Participate in World Antimicrobial Resistance Congress 2018

YONKERS, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- [ContraFect Corporation \(Nasdaq:CFRX\)](#), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in a keynote address entitled "Can non-traditional be our next line of defense? Challenges in non-traditional development, stewardship and diagnostic approaches" at the World Antimicrobial Resistance Congress 2018 on Friday, October 26, 2018 at 9:45 AM ET in Washington, D.C.

Topics of the keynote address include: the most promising and commercially viable non-traditional therapeutics in the pipeline; action plans for further development, partnered diagnostic development, and stewardship implications; clinical trial regulation and approval pathways for non-traditional therapeutics; and regulator, industry and payer involvement in new and non-traditional therapeutics. Dr. Gilman will provide industry perspective on the development of alternative therapeutics to treat bacterial infections.

### About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant *Staph aureus*) and influenza. ContraFect's lead product candidate, CF-301, is currently in a Phase 2 clinical trial for the treatment of *Staphylococcus aureus* bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S. ContraFect is also conducting research focused on the discovery of lysins to target Gram-negative bacteria.

### Forward-Looking Statements:

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws.

Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, whether our initial product candidates can treat antibiotic-resistant infections such as MRSA and influenza, our ability to discover new lysins targeting Gram-negative bacteria, the potential for CF-301 to be a treatment for *Staph aureus* bacteremia, including endocarditis, and statements made regarding the keynote address. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

#### **Investor Relations Contacts:**

Michael Messinger  
ContraFect Corporation  
Tel: 914-207-2300  
Email: [mmessinger@contrafect.com](mailto:mmessinger@contrafect.com)

Matthew Shinseki  
Stern Investor Relations  
Tel: 212-362-1200  
Email: [matthew@sternir.com](mailto:matthew@sternir.com)



Source: ContraFect Corporation